Revvity Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 119.20.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Revvity Inc's Score
Industry at a Glance
Industry Ranking
33 / 205
Overall Ranking
120 / 4521
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Revvity Inc Highlights
StrengthsRisks
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 12.14%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 12.14%.
Fairly Valued
The company’s latest PE is 49.11, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 117.68M shares, decreasing 7.18% quarter-over-quarter.
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.